Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.
brain metastases
breast cancer
estrogen/progesterone/HER2 receptor discordance
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
29 09 2020
29 09 2020
Historique:
pubmed:
9
2
2020
medline:
28
4
2021
entrez:
9
2
2020
Statut:
ppublish
Résumé
Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM). A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM. The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors-nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17-28 mo, P = 0.12; HER2, 15-19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27-18 mo, P = 0.02; HER2, 30-18 mo, P = 0.08). Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly. 1. Receptor discordance alters subtype in 32% of BCBM patients.2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively.3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment.
Sections du résumé
BACKGROUND
Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM).
METHODS
A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM.
RESULTS
The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors-nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17-28 mo, P = 0.12; HER2, 15-19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27-18 mo, P = 0.02; HER2, 30-18 mo, P = 0.08).
CONCLUSIONS
Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly.
KEY POINTS
1. Receptor discordance alters subtype in 32% of BCBM patients.2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively.3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment.
Identifiants
pubmed: 32034917
pii: 5731396
doi: 10.1093/neuonc/noaa025
pmc: PMC7523450
doi:
Substances chimiques
Biomarkers, Tumor
0
Estrogens
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1359-1367Subventions
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA077598
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Breast Cancer (Dove Med Press). 2015 Dec 10;7:381-8
pubmed: 26677343
Breast Cancer Res. 2000;2(6):400-7
pubmed: 11250733
J Clin Oncol. 2015 Aug 20;33(24):2695-704
pubmed: 26195705
Breast Cancer Res. 2010;12(6):R92
pubmed: 21059212
Front Oncol. 2019 Mar 04;9:99
pubmed: 30886831
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Cancer. 2005 Sep 5;93(5):552-6
pubmed: 16106267
Breast Cancer Res. 2010;12(5):R75
pubmed: 20863372
Anticancer Res. 2017 Sep;37(9):4859-4865
pubmed: 28870906
J Clin Oncol. 2012 Jul 20;30(21):2601-8
pubmed: 22711854
Ann Oncol. 2011 Dec;22(12):2597-2603
pubmed: 21427063
Oncologist. 2015 May;20(5):466-73
pubmed: 25802405
J Neurooncol. 2018 Apr;137(2):295-302
pubmed: 29260362
Oncologist. 2008 Nov;13(11):1134-6
pubmed: 18987048
J Natl Cancer Inst. 2018 Jun 1;110(6):568-580
pubmed: 29315431
Med Hypotheses. 2005;64(6):1182-7
pubmed: 15823713
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Neurooncol. 2008 Nov;90(2):223-8
pubmed: 18648908
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Ann Oncol. 2009 Sep;20(9):1499-1504
pubmed: 19299408
Cancer Cell. 2007 Mar;11(3):259-73
pubmed: 17349583
Med Mol Morphol. 2011 Mar;44(1):15-20
pubmed: 21424932
J Clin Oncol. 2012 Feb 1;30(4):419-25
pubmed: 22203767
Anticancer Res. 2009 May;29(5):1557-62
pubmed: 19443366
Breast Cancer Res. 2012 Aug 16;14(4):R119
pubmed: 22898337
Br J Cancer. 2016 Mar 29;114(7):793-800
pubmed: 26908328
Indian J Surg Oncol. 2016 Dec;7(4):397-406
pubmed: 27872526
Cancer. 2011 Feb 15;117(4):705-13
pubmed: 20939012
Exp Ther Med. 2010 Jul;1(4):561-567
pubmed: 22993576
Int J Mol Sci. 2016 Sep 13;17(9):
pubmed: 27649142
J Clin Oncol. 2012 Feb 20;30(6):587-92
pubmed: 22124102
Eur J Cancer. 2014 Jan;50(2):277-89
pubmed: 24269135
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2111-7
pubmed: 21497451
J Cancer Res Clin Oncol. 2013 Nov;139(11):1909-16
pubmed: 24037487
Nature. 2011 Apr 7;472(7341):90-4
pubmed: 21399628
Hum Pathol. 2012 Mar;43(3):398-404
pubmed: 21840040
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):334-343
pubmed: 32084525
BMC Cancer. 2018 Feb 20;18(1):203
pubmed: 29463223